How gene therapy is emerging from its ‘dark age’
By Gemma Conroy,
Nature
| 12. 14. 2022
In a landmark 1972 paper1, physician Theodore Friedmann and biochemist Richard Roblin foresaw a future in which DNA could be manipulated to help treat human genetic diseases. But they cautioned that it should remain off-limits until the field gained a firmer grasp of genetic processes in cells, their relationship to disease and the potential side effects of treatments.
Over the following years, scientists began to remove these obstacles, and in 1990 achieved a major breakthrough when a four-year-old girl with a form of severe combined immunodeficiency disease was successfully treated in a clinical trial2. This ushered in a decade of high hopes and bold promises.
But the afterglow of that early achievement proved short-lived, as a labyrinth of technical challenges emerged. A common gene-therapy approach involves delivering a healthy gene to cells that have only defective copies in their genetic libraries. Once inside, the therapeutic gene instructs the cells to manufacture functional proteins instead of faulty ones. One difficulty has been making sure a treatment gene zeroes in on the correct cells in the right tissue, and is shuttled into...
Related Articles
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...
By Roni Caryn Rabin, The New York Times | 08.25.2025
Scientists have dreamed for centuries about using animal organs to treat ailing humans. In recent years, those efforts have begun to bear fruit: Researchers have begun transplanting the hearts and kidneys of genetically modified pigs into patients, with varying degrees...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...